Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Checkmate Pharmaceuticals, Inc is a biotechnology business based in the US. Checkmate Pharmaceuticals shares (CMPI) are listed on the NASDAQ and all prices are listed in US Dollars. Checkmate Pharmaceuticals employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$6.76|
|52-week range||$5.00 - $23.10|
|50-day moving average||$6.04|
|200-day moving average||$10.06|
|Wall St. target price||$22.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||9.39%|
|3 months (2021-04-29)||5.96%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-43.35%|
|Return on equity TTM||-76.89%|
|Market capitalisation||$118.1 million|
TTM: trailing 12 months
There are currently 141,671 Checkmate Pharmaceuticals shares held short by investors – that's known as Checkmate Pharmaceuticals's "short interest". This figure is 71.2% down from 491,576 last month.
There are a few different ways that this level of interest in shorting Checkmate Pharmaceuticals shares can be evaluated.
Checkmate Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Checkmate Pharmaceuticals shares currently shorted divided by the average quantity of Checkmate Pharmaceuticals shares traded daily (recently around 108977.69230769). Checkmate Pharmaceuticals's SIR currently stands at 1.3. In other words for every 100,000 Checkmate Pharmaceuticals shares traded daily on the market, roughly 1300 shares are currently held short.
However Checkmate Pharmaceuticals's short interest can also be evaluated against the total number of Checkmate Pharmaceuticals shares, or, against the total number of tradable Checkmate Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Checkmate Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Checkmate Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0372% of the tradable shares (for every 100,000 tradable Checkmate Pharmaceuticals shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Checkmate Pharmaceuticals.
Find out more about how you can short Checkmate Pharmaceuticals stock.
We're not expecting Checkmate Pharmaceuticals to pay a dividend over the next 12 months.
Checkmate Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.